ValiRx, the AIM listed life sciences firm, saw its share price surge on news that its 'gene-silencing' technology has received patent approval in Canada.
It already has patents for the US, Europe and Australia.
ValiRx is developing treatments which "silence" so called rebellious genes that can cause cancer and various neurological problems.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The firm also announced today that it has extended its agreement with Imperial College London for cancer therapeutic work.
Production of ValiRx's main "VAL101" compound is "going to plan and has been optimised and simplified." The company argues this will reduce costs and add future value.
Dr. Satu Vainikka, ValiRx's Chief Executive, said of the patent grant: "The filing of this latest patent extends our global geographic patent coverage and I believe it represents a value marker for the company, as we further progress the GeneICE pre-clinical programme."
At 9:13am shares in the company were at 0.502p, a rise of 14.2% on the day. This year ValiRx has seen its value rise 99%.
BS
-
Investors should plan for an age of uncertainty and upheavalTectonic geopolitical and economic shifts are underway. Investors need to consider a range of tools when positioning portfolios to accommodate these changes
-
Investing in UK universities: spin research into profitsUK universities are a vital economic asset, but they are also Britain's 'equivalent of Gulf oil.' There are opportunities here for investors
